Can a neighborhood talk save lives? prostate cancer education trial shows promise
NCT ID NCT03197896
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a neighborhood-based educational program could increase knowledge about prostate cancer and screening among 239 men living in high-risk areas. Participants learned about the pros and cons of screening, and researchers measured changes in decision-making confidence and screening intent. The goal was to reduce disparities by helping men make informed choices, not to treat the disease itself.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this approach could help reduce prostate cancer disparities by increasing informed screening decisions in high-risk communities.
- What could go wrong
- This is a completed educational study, not a treatment trial. It measured knowledge and intent, not actual cancer outcomes, so real-world impact on cancer rates is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug cocktail before surgery curb prostate Cancer's return?
- AI could slash MRI scan times without sacrificing quality
- New prostate surgery technique aims to shorten operation time
- Could a PARP inhibitor slow prostate cancer recurrence?
- New surgical clip tool tested in 161 patients
- New drug SYS6043 targets Hard-to-Treat cancers in early trial